On the cover (left to right):

Top row:

JOSE BASELGA, MD, PhD, FAACR
The AACR President for 2015-2016, Dr. Baselga is Physician-in-Chief at Memorial Sloan Kettering Cancer Center, New York, New York.

CARLOS L. ARTEAGA, MD, FAACR
The AACR President for 2014-2015, Dr. Arteaga is Director of the Center for Cancer Targeted Therapies and the Breast Program and SPORE at Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.

Bottom row:

SERGIO RAMIREZ
Diagnosed with childhood lymphoblastic leukemia, Sergio participated in a clinical trial and is beating the disease thanks to the immunotherapeutic blinatumomab.

JAMEISHA BROWN
Diagnosed with cancer at the age of eight, Jameisha has been cancer-free for 17 years and now conducts research on cancer health disparities.

LORI CUFFARI
Since starting lenvatinib, Lori’s Hurthle cell cancer is no longer visible and she is living a normal life, eating what she wants, and looking forward to the future.

BRINGING CANCER DISCOVERIES TO PATIENTS
MISSION AND VISION

The mission of the American Association for Cancer Research (AACR) is to prevent and cure cancer through research, education, communication, and collaboration. Through its programs and initiatives, the AACR fosters research in cancer and related biomedical science, accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

VISION

To be the most effective catalyst for cures and prevention through cancer science.

HISTORY

The AACR is the world’s first and largest cancer research organization dedicated to accelerating the prevention and cure of cancer. Founded in 1907 by nine physicians and two laboratory scientists, the AACR has more than 35,000 members in 101 countries. Learn more about the history of the AACR at AACR.org/history.
BRINGING CANCER DISCOVERIES TO PATIENTS

The theme of the AACR Annual Meeting 2015, “Bringing Cancer Discoveries to Patients,” is also the theme of this report. It emphasizes the critical role each step along the cancer science continuum, from basic discoveries to translational advances to clinical impact, plays in our mission. With 35,000 members working in every discipline along that continuum, the AACR is uniquely positioned to improve the lives of cancer patients in myriad ways.

Research
The AACR identifies and fosters innovative science that is of the highest priority for impact in reducing cancer incidence, morbidity, and mortality. One of the AACR’s major mechanisms for accomplishing this goal is to promote high-quality science through its Scientific Review and Grants Administration program. The AACR provides scientific oversight and expert peer review to ensure that the most promising projects receive essential funding. Working with funding partners throughout the cancer community, the AACR awarded nearly $70 million in grants to exceptional investigators in 2015. The AACR also fosters innovation and recognizes the meritorious work of investigators and their impact on the field through Scientific Achievement Awards and election as Fellows of the AACR Academy.

Education
The AACR’s scientific journals and conferences provide leading investigators with a vital forum for sharing the latest discoveries, using the page and the podium to disseminate cutting-edge cancer science in all disciplines. The AACR also fosters dialogue among the various stakeholders in the cancer community. Through briefings, workshops, and the AACR Cancer Progress Report, the Office of Science Policy and Government Affairs keeps lawmakers, regulators, and the public informed about the critical value of cancer research. In addition, Cancer Today magazine and the Survivor and Patient Advocacy program provide authoritative knowledge that empowers patients, caregivers, and patient advocates to meet the challenges of a cancer diagnosis.

Collaboration
With members in 132 countries and a longstanding reputation for scientific excellence, the AACR forging partnerships with scientific and advocacy organizations worldwide to advance science for the benefit of all cancer patients. In addition, the AACR’s multidisciplinary meetings, workshops, and task forces bring investigators from academia, government, and industry together, breaking down silos and building productive relationships.

Cancer is a complex disease, and achieving our mission to prevent and cure cancer requires a concerted effort in a wide range of scientific and policy areas. As this report demonstrates, the AACR is actively engaged in these areas, supporting the community that will translate our increasing understanding of the cancer problem into solutions.

WELCOME
We are pleased to present the 2015 Annual Report of the American Association for Cancer Research (AACR). The report highlights the AACR’s progress over the past year in support of our mission: to prevent and cure cancer through research, education, communication, and collaboration.

The AACR sustains the pipeline of cancer scientists at all career levels. Special programs inspire high school students and undergraduates to pursue careers in cancer research, and educational workshops traditionally guide scientists to share their research findings and learn about the latest developments in all disciplines. The AACR also educates advocates through its highly regarded Scientist↔Survivor Program, pairing them with mentors who provide the scientific context for their vitally important work in the cancer field.

Communication
The AACR's scientific journals and conferences provide leading investigators with a vital forum for sharing the latest discoveries, using the page and the podium to disseminate cutting-edge cancer science in all disciplines. The AACR also fosters dialogue among the various stakeholders in the cancer community. Through briefings, workshops, and the AACR Cancer Progress Report, the Office of Science Policy and Government Affairs keeps lawmakers, regulators, and the public informed about the critical value of cancer research. In addition, Cancer Today magazine and the Survivor and Patient Advocacy program provide authoritative knowledge that empowers patients, caregivers, and patient advocates to meet the challenges of a cancer diagnosis.

Collaboration
With members in 132 countries and a longstanding reputation for scientific excellence, the AACR forges partnerships with scientific and advocacy organizations worldwide to advance science for the benefit of all cancer patients. In addition, the AACR’s multidisciplinary meetings, workshops, and task forces bring investigators from academia, government, and industry together, breaking down silos and building productive relationships.

Cancer is a complex disease, and achieving our mission to prevent and cure all cancers requires a concerted effort in a wide range of scientific and policy areas. As this report demonstrates, the AACR is actively engaged in these areas, supporting the community that will translate our increasing understanding of the cancer problem into solutions.

OUR MISSION IS AMBITIOUS. TOGETHER, WE WILL ACHIEVE IT.
Research increases understanding of the collection of diseases known as cancer and allows the translation of knowledge into new and increasingly precise ways to prevent, detect, diagnose, treat, and cure many of these diseases. In 2015 alone, research fueled U.S. Food and Drug Administration (FDA) approval of 16 new anticancer therapeutics and seven new uses for previously approved anticancer therapeutics.

Nine of the newly approved drugs — alectinib (Alecensa), cobimetinib (Cotelli), daratumumab (Darzalex), elotuzumab (Empliciti), lenvatinib (Lenvima), necitumumab (Portrazza), osimertinib (Tagrisso), palbociclib (Ibrance), and sonidegib (Odomzo) — target specific molecules involved in cancer and are referred to as molecularly targeted therapeutics. They are part of the precision medicine revolution that is ensuring that more people are living longer, higher-quality lives after a cancer diagnosis.

Four of the newly approved drugs — daratumumab (Darzalex), dinutuximab (Unituxin), elotuzumab, and talimogene laherparepvec (Imlygic) — work by harnessing the power of a patient’s own immune system to fight his or her cancer, which demonstrates the emergence of cancer immunotherapy as a key pillar of care. The power of cancer immunotherapy lies in the remarkable and durable responses experienced by patients with a variety of types of cancer.

The American Association for Cancer Research (AACR) is proud to have helped catalyze the progress made against cancer in 2015 through its many programs, services, and initiatives. For example, early results from the clinical trial that led to the October 2015 FDA approval of the immunotherapeutic pembrolizumab (Keytruda) for treating certain patients with non–small cell lung cancer were first disseminated at the AACR Annual Meeting 2015.

With one in two men and one in three women in the U.S. expected to be diagnosed with cancer in their lifetimes, it is vital that the AACR communicates the spectacular advances against cancer to all sectors of the American population. The annual AACR Cancer Progress Report is a cornerstone of the AACR’s efforts to increase public understanding of cancer and the importance of cancer research to public health, and to advocate for increased federal funding for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the FDA.

The AACR Cancer Progress Report 2015 chronicles how federally funded research spurred progress against cancer in 2015 and showcases the fact that the number of FDA-approved molecularly targeted anticancer therapeutics more than doubled in the past five years.

As AACR President (2015–2016) José Baselga, MD, PhD, FAACR, stated in the report, “...these are exciting times and...the pace of discovery and application of new knowledge to patient care is rapidly accelerating.”

Right: Survivors featured in the AACR Cancer Progress Report 2015. The annual AACR Cancer Progress Report is a cornerstone of the AACR’s efforts to increase public understanding of cancer and the importance of cancer research to public health, and to advocate for increased federal funding for cancer research.

Renata Pasqualini, PhD (right) and her husband Wadih Arap, MD, PhD, at their joint laboratory at the University of New Mexico Comprehensive Cancer Center. An AACR Career Development Grantee, Dr. Pasqualini was motivated to pursue a career in medical research by her mother’s breast cancer diagnosis and successful treatment.
All of the stakeholders in cancer research come together at the AACR Annual Meeting. The 2015 Annual Meeting was the largest in history, with over 19,300 scientists, clinicians, patients, and advocates from 71 countries gathered in the AACR’s home city of Philadelphia to share the latest cancer science.

Sharing Scientific Knowledge
Basic and translational scientists and clinical investigators converged at poster boards and plenary sessions to present the full spectrum of cancer discovery.

Mentoring Future Innovators
Leaders in all fields fostered the next generation of cancer researchers, engaging with high school student, undergraduates, and early-career scientists in career development sessions to offer inspiration, encouragement, and practical advice.

Navigating Regulatory Science
Academic and industry scientists interacted with regulatory agencies in Regulatory Science and Policy sessions, fostering dialogues and accelerating the discovery and development of new diagnostics and treatments.

Educating Survivors and Advocates
In the AACR Scientist↔Survivor Program, scientists provided survivors and advocates with a vital scientific context for the discoveries presented. In turn, survivors and advocates provided a critical patient perspective for scientists to bring back to their laboratories and clinics.
ANNUAL MEETING SETTING THE RESEARCH AGENDA

The theme of the Annual Meeting, Bringing Cancer Discoveries to Patients, underscored the link between discovery and treatment. The multidisciplinary program included researchers from across the continuum of cancer science, from population science, to basic, translational, and clinical cancer research. Highlights of the cutting-edge research presented at the meeting were summarized by AACR leaders in a closing plenary session.

During the closing plenary, Kevin C. Cantley, PhD, FAACC, AACR chairperson of the 2015 Annual Meeting Program Committee, discussed key research presentations. These included numerous studies investigating genetic diversity among different cells isolated from a single tumor and among tumors isolated from different sites in a single patient. He emphasized the critical value of mapping this genetic heterogeneity and understanding how it evolves because the information is vital to understanding and overcoming treatment resistance. Cantley also highlighted presentations that revealed mechanisms of resistance to specific molecularly targeted therapies and how a combination of basic research approaches—including proteomics, systems biology, organoids, and CRISPR-Cas9 technology—are being used to overcome this challenge and analyze the development of new targeted therapies.

William G. Nelson, MD, PhD, editorial chief of Cancer Today, highlighted key presentations on cancer prevention research, in particular those in the emerging field of precision prevention and early detection. He focused on studies developing and using molecular tools for screening and early detection, such as the DNA stool test for colorectal cancer, and went on to discuss the use of genomics to identify individuals who are at highest risk for certain cancers and might benefit from chemoprevention approaches such as taking aspirin for colorectal cancer prevention. Nelson concluded his summary with studies suggesting the role of the microbiome has an important role in cancer biology, focusing on preclinical data showing that a particular bacterium promotes colorectal cancer development in a mouse model of the disease.

José Baselga, MD, PhD, FAACC, AACR president 2015–2016, concluded the session with a vision for the future—a future in which the promise of precision medicine, immunotherapy, and the harnessing of big data is fully realized.
ANNUAL MEETING
AT A GLANCE

Record-setting Number of Attendees in Philadelphia

19,300 People attended the meeting. The Annual Meeting 2015 was the largest in the history of the AACR.
71 Countries were represented at the meeting.
5,820 Papers were presented in poster sessions or minisymposia.

A Dynamic Scientific Program Highlights Cutting-edge Clinical Research

101 Clinical trials were presented at the meeting, including a phase III study of pembrolizumab versus ipilimumab in patients with advanced melanoma. Featured in the opening plenary session, the randomized trial was the first to compare two FDA-approved immune checkpoint inhibitors as first-line therapy. The results of the study indicate that pembrolizumab yielded significantly better outcomes than ipilimumab, which is the current standard of care.

Presentation of the trial was followed by a discussant, who placed the clinical results in biological context for an audience that spanned the continuum from basic to translational to clinical scientists. Because of the AACR’s unique ability to bring together the full spectrum of cancer investigators, clinical trials presented at the AACR Annual Meeting go beyond changing practice; they also advance the science.

783 Scientists participated as invited speakers, sharing their expertise and their data with the cancer community.

244 Scientific sessions provided a diverse forum for leading investigators, including 48 major symposia and five plenary sessions. For the first time in 2015, the meeting featured a closing plenary session that summarized the key themes of the meeting and offered a vision of the future, providing attendees with a first draft of the research agenda for the coming year.

1,228 Physicians scientists and clinicians claimed Continuing Medical Education (CME) credits for attending the meeting. The AACR has offered CME credit for Annual Meeting attendees since 1983.

1,176 Physicians claimed CME credit for attending the meeting. The AACR has offered CME credit for Annual Meeting attendees since 1983.

50 News releases were distributed.
166 Reporters attended.
2,100+ Media stories were generated.

ANNUAL MEETING
GENERATING TOP-TIER MEDIA COVERAGE

The AACR Annual Meeting 2015 produced a record amount of news coverage and social media interest, strengthening the organization’s brand as the authoritative voice and resource in cancer research.

Media Impact

50 News releases were distributed.
166 Reporters attended.
2,100+ Media stories were generated.
19,176 Tweets mentioned the Annual Meeting.
4,245 Tweets referenced the #AACR15 hashtag — which trended at #1 worldwide on Sunday, April 19.
406 Scientists, clinicians, patients, and advocates participated in the second annual ABC News Twitter chat from the Annual Meeting — including the AACR’s first live broadcast on Periscope.
2,300 Tweets were sent during the chat.

Among the many news organizations covering the Annual Meeting were the following major media outlets:
Cancer knows no boundaries. Neither does the AACR. Thirty percent of AACR members are located outside the U.S. With a member presence in 101 countries—and with satellite offices in Canada and China—the AACR reaches across national borders to promote scientific excellence, working with numerous organizations to provide forums for cutting-edge research from around the world. Through scientific conferences, educational workshops, and financial support, the AACR ensures that the cancer research community is as geographically diverse as the patients it serves.

New Horizons Conference Series Continues
The second edition of the conference on New Horizons in Cancer Research was held in Shanghai, China, in November 2015. Co-chaired by AACR President Carlos L. Arteaga, MD, FAACR, and Annual Meeting Program Chairperson Lewis C. Cantley, PhD, FAACR, the program combined highlights from the AACR Annual Meeting 2015 with presentations from international speakers and local experts to cover the full spectrum of cancer research.

International Collaborations Foster Innovative Science
Working with international scientific organizations, the AACR organized six joint conferences and workshops in 2015:

- EACR-AACR-SIC Special Conference on Anticancer Drug Action and Drug Resistance: from Cancer Biology to the Clinic, Florence, Italy, June 2015
- ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research, Flims, Switzerland, June 2015
- AACR-N21 FORTE Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts, November 2015

Emerging Partnerships Bring Cutting-edge Science to New Audiences
AACR-sponsored sessions at international meetings in 2015 included the following:

- Pre-conference workshop on “Follicular Lymphoma: Recent Insights and Future Directions” and two lectures, 13th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2015
- “Precision Medicine,” African Organization for Research and Training in Cancer (AORTIC) Annual Meeting, Marrakech, Morocco, April 2015

Exchanging Ideas, Building Relationships
The AACR further strengthened its relationship with the Chinese Society of Clinical Oncology (CSCO) in 2015, organizing joint sessions at the annual meeting for each organization:

- “Lung Cancer,” CSCO Annual Meeting, Xian, China, September 2015
Established in 2013, the AACR Academy recognizes and honors distinguished scientists whose contributions have consistently propelled significant innovation and progress against cancer. While election as a Fellow of the AACR Academy (FAACR) is a great honor for current accomplishments, it is also an opportunity to guide the future of cancer research. Fellows engage with colleagues, lawmakers, and the public to discuss important issues and catalyze progress against cancer.

At a ceremony on the evening before the Annual Meeting, the 2015 Class of Fellows of the AACR Academy were formally inducted. On June 17, several Fellows of the AACR Academy joined AACR leaders, congressional representatives, and the White House Office of Science and Technology Policy to host a special briefing titled “Saving Lives in the New Era of Precision Medicine.” The participants discussed the dynamic potential of precision medicine and called upon Congress to provide robust and sustained increases in funding to the National Institutes of Health and the National Cancer Institute.

The success of the AACR’s mission to prevent and cure cancer depends upon an appreciation of the past and a vision of the future. It requires an understanding of the critical discoveries that have shaped the current scientific paradigm as well as the wisdom and foresight to shift that paradigm when necessary.

HONORING SCIENTIFIC ACHIEVEMENT

FELLOWS OF THE AACR ACADEMY

Recognizing Scientific Accomplishment

Class of 2015

Left to right:

KENNETH C. ANDERSON, MD, FAACR
Dana-Farber Cancer Institute
Boston, Massachusetts

BRUCE A. CHABNER, MD, FAACR
Massachusetts General Hospital
Boston, Massachusetts

RONALD A. DEPINHO, MD, FAACR
The University of Texas MD Anderson Cancer Center
Houston, Texas

DOUGLAS R. LOWY, MD, FAACR
National Cancer Institute
Bethesda, Maryland

CAROL L. PRIVES, PHD, FAACR
Columbia University
New York, New York

CARLOS L. ARTEAGA, MD, FAACR
Vanderbilt-Ingram Cancer Center
Vanderbilt University
Nashville, Tennessee

ANTON J.M. BERNS, PHD, FAACR
Netherlands Cancer Institute
Amsterdam, Netherlands

SUSAN D. DESMOND-HELLMANN, MD, MPH, FAACR
Bill and Melinda Gates Foundation
Seattle, Washington

ROBERT N. EISENMAN, PHD, FAACR
Fred Hutchinson Cancer Research Center
Seattle, Washington

STEVEN A. ROSENBERG, MD, PHD, FAACR
National Cancer Institute
Bethesda, Maryland

CRAIG B. THOMPSON, MD, FAACR
Memorial Sloan Kettering Cancer Center
New York, New York

The induction ceremony for the 2015 Class of Fellows of the AACR Academy took place at the Franklin Institute in Philadelphia during the AACR Annual Meeting 2015.
Brilliant scientists dedicate their careers to making the discoveries that enable them to understand, prevent, treat, and cure cancer. Through Scientific Achievement Awards and Lectureships, the AACR fosters innovation and honors exceptional investigators for their contributions.

For example, the AACR Team Science Award was created to recognize the importance of interdisciplinary collaboration to capitalize on the unparalleled opportunities made possible by the sequencing of the human genome, progress in systems biology, and the emergence of computational technologies. In addition to honoring scientific achievement, the AACR also recognizes the importance of champions of cancer research. The AACR Margaret Foti Award celebrates these individuals, whose leadership and sustained commitment to the prevention and cure of cancer have made a major impact on the field.

2015 Scientific Achievement Award Recipients
Starting with the world’s first English-language cancer journal in 1916, AACR journals have provided a publication forum for discoveries that span the breadth of basic, translational, clinical, and epidemiological cancer research. The journals’ editorial boards draw on experts in all disciplines, making AACR publications a trusted resource for the latest advances and providing a strong signal of quality amid the noise of a crowded scientific information landscape.

High Standards, High Impact
An indicator of journal quality is the Impact Factor, which uses article citations to measure the relative importance of a journal within its field:

- The eight AACR journals ranked in the top 30 percent in the oncology category—led by Cancer Discovery, Cancer Research, and Clinical Cancer Research, which rank in the top 9 percent.
- With an Impact Factor of 19.453, Cancer Discovery ranked fifth out of 211 oncology journals.
- Cancer Research continued to be the most frequently cited cancer journal in the world. Clinical Cancer Research ranked third among all oncology journals for number of citations.

Major Milestones in a Proud Publishing Tradition
In 2016, Cancer Research, the longest-running AACR journal, will celebrate its 75th anniversary. In addition, the number of articles published in the journal surpassed 50,000 in 2015.

Clinical Cancer Research marked its 20th year of publication in 2015. Since its launch in 1995, the journal has provided a vital publication outlet for high-impact translational and clinical research, helping to transform molecular and cellular insights into clinical interventions to benefit patients.

Defining the Frontiers of Cancer Science
Since its launch in 2001, Molecular Cancer Therapeutics has been a source of cutting-edge research in the area of small-molecule therapeutics. The journal recently identified large-molecule therapeutics as an emerging area in the field, and the new category has attracted a growing number of high-quality research articles.

Molecular Cancer Research curated special collections of significant journal content in 2015, highlighting critical areas such as the Ras pathway, chromatin regulation, and cell cycle and senescence.

Cancer Prevention Research supported the emerging field of cancer immunoprevention in 2015, commissioning a series of invited articles on the subject and expanding its scope to accommodate an increasing number of preflected articles.

New Editorial Leadership
In September 2015, the AACR appointed Robert D. Schreiber, PhD, and Philip D. Greenberg, MD, as the new editors-in-chief of Cancer Immunology Research. Launched in 2013 under the leadership of Founding Editor Glenn Dranoff, MD, the journal has continued to advance in cancer immunology and immunotherapies that span the spectrum of science and medicine.

Capturing the Interest of the Public Worldwide
As a forum for research on cancer etiology, prevention, and survivorship, Cancer Epidemiology, Biomarkers & Prevention (CEBP) continues to receive significant media attention. In 2015, the AACR issued 20 news releases featuring articles published in CEBP, generating approximately 1,200 media clips from major national and international media outlets, local news stations, and cancer and medical trade publications.

Top Oncology Journals*
1. CA: A Cancer Journal for Clinicians
2. Nature Reviews Cancer
3. Lancet Oncology
4. Cancer Cell
5. Cancer Discovery
6. Journal of Clinical Oncology
7. Nature Reviews Clinical Oncology
8. Journal of the National Cancer Institute
9. Leukemia
10. Seminars in Cancer Biology
11. Cancer Research
12. Clinical Cancer Research

Top 12 Journals (by Impact Factor) out of 211: Journal Citation Reports®, Thomson Reuters 2015.
The editor-in-chief of an AACR journal establishes the publication’s scientific vision, appoints an editorial board to support that vision, and maintains the journal’s ethical integrity. The AACR thanks the following editors-in-chief for their hard work and stewardship of its scientific publishing program.

- **LEWIS C. CANTLEY, PHD, FAACR**
  - Memorial Sloan Kettering Cancer Center
  - New York, New York

- **TIMOTHY R. REBBECK, PHD**
  - Dana-Farber Cancer Institute
  - Boston, Massachusetts

- **ROBERT D. SCHREIBER, PHD**
  - Washington University School of Medicine
  - St. Louis, Missouri

- **PHILIP D. GREENBERG, MD**
  - Fred Hutchinson Cancer Research Center
  - Seattle, Washington

- **SCOTT H. LIPPMAK, MD**
  - UC San Diego Moores Cancer Center
  - San Diego, California

- **GEORGE C. PRENDERGAST, PhD**
  - Lankenau Institute for Medical Research
  - Wynnewood, Pennsylvania

- **KENNETH C. ANDERSON, MD, FAACR**
  - Dana-Farber Cancer Institute
  - Boston, Massachusetts

- **KAREN E. KNUDSEN, PHD**
  - Kimmel Cancer Center
  - Philadelphia, Pennsylvania

- **NAPOLEONE FERRARA, MD, FAACR**
  - UC San Diego Moores Cancer Center
  - San Diego, California
MEETINGS AND WORKSHOPS

FORGING CONNECTIONS, BUILDING COMMUNITY, AND ADVANCING SCIENCE

The AACR also hosts educational workshops and special courses focused on the vital mission of developing the next generation of investigators. Workshops train early-career scientists in clinical trial design, molecular biology, molecular epidemiology, and related fields. World-renowned experts on the faculty supplement educational programs with mentoring, networking, and career development opportunities—transforming a class of promising scientists into a network of future collaborators.

In addition to scientific excellence, the defining characteristic of AACR meetings is collaboration—across disciplines, across institutions, and across national borders. Seven conferences on the AACR calendar were held outside the United States, and nine conferences were organized in partnership with one or more scientific organizations. By fostering these collaborative relationships, AACR meetings and workshops provide a forum for cutting-edge science while creating a community that will maximize its impact.

AACR meetings provide a dynamic, open environment to communicate the latest advances in cancer science and medicine. The AACR convened 33 meetings in 2015, the most in its history. The meetings are crafted to meet the varied needs of the research community, and they range from small conferences on specific disease sites and emerging scientific areas to larger gatherings on topics of general interest such as molecular targets, basic science, and cancer health disparities.

SCIENCE AND EDUCATION

Members of the QuadW-AACR Sarcoma Expert Panel, which met in September 2015 to discuss the future of sarcoma research and improved patient outcomes:

Laurence Zitvogel, MD, PhD, delivers a keynote lecture on “The impact of gut microbiota in cancer development and therapeutics” at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in November 2015.
May 6-8; Bethesda, Maryland

AGENT DEVELOPMENT AND VALIDATION
● Co-chairpersons: Rakesh K. Jain, PhD, Lynda Chin, MD, William R. Sellers, PhD, FAACR, and Cornelis J.M. Melief, PhD

NORMALIZATION: BENCH TO BEDSIDE TO CLINICAL TRIALS

COACHING IN CANCER BIODRUGS: TUMOR FACTORS IN CLINICAL TRIALS

COACHING IN CANCER BIODRUGS: ASCORBATE IN CLINICAL TRIALS

June 7-10; Bellevue, Washington

COMPUTATIONAL AND SYSTEMS BIOLOGY
● Co-chairpersons: Dean W. Felsher, MD, PhD, and Michael D. Taylor, MD, PhD

INTERNATIONAL CONFERENCE MEETING HELD OUTSIDE U.S.

June 20-23; Florence, Italy

AACR-SIC-EACR JOINT CONFERENCE: MALIGNANT LYMPHOMA
13TH INTERNATIONAL CONFERENCE ON TRANSLATING SCIENCE INTO SURVIVAL

July 25-31; Vail, Colorado

EPIDEMIOLOGY
● Co-chairpersons: Robert G. Maki, MD, PhD, Lee J. Helman, MD, and Scott Weiss, MD, MS

August 10-14; Boston, Massachusetts

EPIDEMIOLOGY
● Co-chairpersons: Charles L. Sawyers, MD, PhD, and Scott Weiss, MD, MS

September 24-27; Atlanta, Georgia

CANCER RESEARCH CURRICULUM SERIES WORKSHOP: HOW TO WRITE A SCIENTIFIC ABSTRACT

October 23-26; Philadelphia, Pennsylvania

BRAIN MALIGNANCIES
● Co-chairpersons: Kathy R. Cho, MD, PhD, Marc Berdah, MD, and Scott Weiss, MD, MS

November 3-4; Salt Lake City, Utah

DEVELOPMENTAL BIOLOGY AND CANCER SYMPOSIUM

November 9-13; Boston, Massachusetts

ADVANCED CANCER RESEARCH SYMPOSIUM

November 30-December 3; Austin, Texas

CANCER GENETICS & GENOMICS AND CANCER RESEARCH SYMPOSIUM

November 30-December 3; Boston, Massachusetts

CANCER UNDERSTANDING, CITIZEN SCIENCE, AND COMMUNITY ENGAGEMENT WORKSHOP

November 30-December 3; Boston, Massachusetts

CANCER UNDERSTANDING, CITIZEN SCIENCE, AND COMMUNITY ENGAGEMENT WORKSHOP

November 9-13; Boston, Massachusetts

ADVANCED CANCER RESEARCH SYMPOSIUM

November 8-13; Boston, Massachusetts

ADVANCED CANCER RESEARCH SYMPOSIUM

November 3-4; Salt Lake City, Utah

DEVELOPMENTAL BIOLOGY AND CANCER SYMPOSIUM

November 9-13; Boston, Massachusetts

ADVANCED CANCER RESEARCH SYMPOSIUM

November 3-4; Salt Lake City, Utah

DEVELOPMENTAL BIOLOGY AND CANCER SYMPOSIUM

November 8-13; Boston, Massachusetts

ADVANCED CANCER RESEARCH SYMPOSIUM

November 8-13; Boston, Massachusetts

ADVANCED CANCER RESEARCH SYMPOSIUM
THINK TANKS

AACR MEMBERS DRIVING INNOVATION

The most respected minds in the cancer research community convene to identify and nurture emerging scientific areas through AACR Think Tanks. These forums support and encourage open dialogue, shaping the next wave of innovations in cancer science. The action-oriented conversations continue well beyond the conference table, sparking collaborations that catalyze change.

Inaugural AACR Radiation Oncology Think Tank: Optimizing Cancer Care Through Advancements in Radiation Science and Medicine
January 11–13, Fort Myers, Florida
Chairpersons: Theodore S. Lewis, MD, PhD
Goal: To provide a forum for radiation oncologists, nurses, and distinguished investigators in other oncology fields to focus on radiation science and medicine, exploring the challenges and opportunities across all specialties.

QuadW–AACR Sarcoma Expert Panel: Envisioning the Future of Sarcoma Research and Improved Patient Outcomes
September 11–12, Moran, Wyoming
Chairperson: Lee J. Helman, MD
Goal: To convene a diverse group of sarcoma experts to identify and evaluate the most promising areas in the field and to encourage and support young investigators and their research efforts.

AACR-Thomas J. Bardos Science Education Scholar Awards for Undergraduate Students
Twenty-one remarkable undergraduate students attended the AACR Annual Meeting 2015 as Bardos awardees. The program offers students an invaluable opportunity to learn about the latest developments in cancer research, interact with prominent researchers, and form lasting connections with other gifted young scientists.

SCIENCE EDUCATION AND CONTINUING MEDICAL EDUCATION

Developing Current and Future Cancer Research Innovators

The AACR sustains the pipeline of diverse, talented, and engaged cancer researchers through science education programs which nurture students from high school all the way to their first independent position. As physician-scientists and clinicians progress in their careers, the AACR continues their training through its Continuing Medical Education (CME) program. As a fully accredited ACCME CME provider since 2010, the AACR enables clinical investigators to apply critical aspects of basic cancer research to the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer.

Undergraduate Student Caucus and Poster Competition
Undergraduate students learn about careers in cancer research from leaders in the field, who present their groundbreaking research, discuss educational pathways, and offer career development advice at the Annual Meeting. Students also present their own research, receiving feedback from peers as well as from experts. The program marked its 10-year anniversary in 2015, celebrating nearly 700 undergraduate participants since 2006.

Special Program for High School Students
Even the youngest scientists can learn about cancer research directly from experts while presenting their own novel research. In 2015, 350 students from local schools as well as students working in laboratories of AACR members participated in the program. Students at the Annual Meeting heard from guest speakers Devon Still — a former NFL player whose daughter is a neuroblastoma survivor — and Reggie Love, a writer, editor, and former special assistant and personal aide to President Obama.

Continuing Medical Education
The AACR provides physician-scientists and clinicians with a wide range of opportunities to maintain their competence and incorporate new knowledge into their practice. CME credit was offered at 22 different AACR meetings in 2015, including 11 special conferences, three joint conferences, three workshops, and the Annual Meeting. AACR journals provided another educational resource, offering credit to investigators for reading articles as well as for reviewing manuscripts. A total of 3,254 researchers and clinicians claimed CME credit from the AACR in 2015, ensuring that researchers apply the full spectrum of basic, translational, and clinical cancer science to improving the lives of their patients.

Members of the inaugural AACR Radiation Oncology Think Tank, which met in January 2015 to discuss optimizing cancer care through advancements in radiation science and medicine.
The next great advances in cancer research will be achieved only if scientists receive essential research funding. The cancer community has entrusted the AACR with the stewardship of such grant funding for over two decades. Since 1993, the AACR has administered nearly $300 million in research support, providing scientific oversight as well as expert peer review and grants administration that is fast, flexible, rigorous, and transparent.

$60 million
Was awarded in 2015 to fund the research of six new "Dream Teams" through the AACR’s partnership with SU2C.

$6.75 million
Will be awarded over the next five years through the Novartis Grants for Transformative Cancer Research Program. This exciting new program, initiated by AACR Past President Carlos L. Arteaga, MD, FAACR, will provide early-career investigators with the resources they need to conduct creative, paradigm-shifting cancer research that will catalyze major breakthroughs in the field.

$460,000
Was awarded to nine postdoctoral fellows for basic cancer research through an unprecedented expansion of the Basic Cancer Research Fellowship Program. The AACR emphasizes the critical importance of basic research as the foundation of future translational and clinical breakthroughs for cancer patients.
Fostering innovative and collaborative cancer science requires innovative and collaborative funding mechanisms. The AACR is proud to serve as the Scientific Partner of Stand Up To Cancer (SU2C), a groundbreaking movement to accelerate the pace of translational cancer research, get new therapies to patients quickly, and save lives.

As a program of the Entertainment Industry Foundation, SU2C focuses the industry’s resources to increase awareness of the urgent need for cancer research and raise needed funds. The AACR works with SU2C’s Blue Ribbon Scientific Advisory Committee (SAC) to conduct rigorous, peer review, identifying the most promising research projects to fund and providing expert scientific oversight for those projects. The committee is composed of highly accomplished clinical researchers, senior laboratory researchers, and physician-scientists from the AACR membership as well as patient advocates experienced in grant review and clinical trials. The chairpersons of the committees is Nobel Laureate Phillip A. Sharp, PhD, FAACR, and Arnold J. Levine, PhD, FAACR, and William G. Nelson, MD, PhD, serves as vice chairpersons.

Since SU2C’s inception in 2008, the AACR has worked with SU2C to launch and administer 19 Dream Teams and two Translational Research Teams of top researchers addressing specific problems in cancer, as well as 26 Innovative Research Grants to individual, early-career investigators to support high-risk projects that also have a high level of potential impact on the prevention or treatment of cancer. As part of its oversight, the AACR organizes an annual SU2C Scientific Summit at which Dream Teams and Innovative Research Grant recipients report on their progress and brainstorm opportunities for new collaborations and accelerated research.

In addition to fostering collaboration among scientists, SU2C fosters collaboration among funders, working with leading cancer organizations worldwide to co-sponsor high-impact research. For example, in 2015 SU2C and the AACR launched Dream Teams focused on ovarian cancer, with the Ovarian Cancer Research Fund Alliance and National Ovarian Cancer Coalition; on lung cancer, with the American Cancer Society; on colorectal cancer, with the Dutch Cancer Society; on pancreatic cancer, with Cancer Research UK and The Lustgarten Foundation; on cancer stem cells in brain cancers, with Genome Canada, Canadian Institutes of Health Research, and Ontario Institute for Cancer Research; and on breast cancer, with the Canadian Breast Cancer Foundation with support from CIBC, and the Ontario Institute for Cancer Research.

With the support of these organizations, SU2C and the AACR are breaking down barriers to progress and building the teams that will solve the cancer problem.

As part of its SU2C Scientific Advisory Committee

- Phillip A. Sharp, PhD, FAACR
- Arnold J. Levine, PhD, FAACR
- William G. Nelson, MD, PhD
- Frederick R. Appelbaum, MD
- Elizabeth H. Blackburn, PhD, FAACR
- Richard B. Gaynor, MD
- William N. Hait, MD, PhD, FAACR
- Lee J. Helman, MD
- Waun Ki Hong, MD, FAACR
- William G. Kaelin Jr., MD, FAACR
- Michael B. Kastan, MD, PhD
- Richard D. Kolodner, PhD, FAACR
- Guillermina Lozano, PhD
- Tak W. Mak, PhD, FAACR
- Cecil B. Pickett, PhD
- Laura K. Shawver, PhD
- Ellen V. Sigal, PhD
- David A. Tuveson, MD, PhD

SU2C Funding Partners

- Melanoma Research Alliance
- Prostate Cancer Foundation
- Cancer Research Institute
- St. Baldrick’s Foundation
- Dutch Cancer Society KWF
- Cancer Research UK
- Lustgarten Foundation
- Farrah Fawcett Foundation
- American Cancer Society
- Ovarian Cancer Research Fund Alliance
- National Ovarian Cancer Coalition
- Canadian Breast Cancer Foundation
- Genome Canada
- Canadian Institute of Health Research
- Ontario Institute for Cancer Research
- Van Andel Research Institute

Left to right: William G. Nelson, MD, PhD (SU2C Scientific Advisory Committee Chairperson; cancer survivor Pearce Quesenberry; SU2C Co-founder Kate Garie; and AACR CEO Margaret Foti, PhD, MD (hc) participate on Facebook’s Facebook Live chat before the SU2C telecast.

Opposite page: Phillip A. Sharp, PhD (top left); SU2C Scientific Advisory Committee Chairperson; Arnold J. Levine, PhD (top right); SU2C Scientific Advisory Committee Vice Chairperson; cancer survivor Pearce Quesenberry; SU2C Co-founder Kate Garie; and AACR CEO Margaret Foti, PhD, MD (hc) participate on Facebook’s Facebook Live chat before the SU2C telecast.
Rally for Medical Research Hill Day

As the founding organizer of the original Rally for Medical Research — held on the streets of Washington during the 2013 Annual Meeting — the AACR forged a coalition of more than 200 organizations and institutions to call for increased federal investment in biomedical research. On September 17, that coalition moved from the streets to Capitol Hill, as more than 300 organizations came together for the Rally for Medical Research Hill Day. The AACR and its partners held more than 200 meetings with members of Congress to advocate for robust, sustained, and predictable increases in funding for the National Institutes of Health (NIH) in 2016 and beyond. This collaborative effort was rewarded in December, when Congress approved an omnibus spending bill that contained a $2 billion increase for the NIH — the first meaningful budgetary increase for the agency in more than a decade.

Congressional Briefings

Education is a critical component of advocacy. The AACR brings leading scientists and clinicians to Capitol Hill to provide members of Congress with the scientific background they need to make informed decisions.

- Electronic Cigarettes. On May 14, Roy S. Herbst, MD, PhD, chair of the AACR Tobacco and Cancer Subcommittee, presented the latest research on electronic nicotine delivery systems (ENDS) and suggested steps lawmakers can take to limit the marketing of these products to young people.
- Diagnostics and Precision Medicine. On June 8, the AACR partnered with AdvaMedDx (an international group of leading manufacturers of in vivo diagnostics) to brief Congress on the leading role played by diagnostics in precision medicine.
- Saving Lives in the New Era of Precision Medicine. On June 17, AACR members Carlos Arteaga, MD, FAACR, José Baselga, MD, PhD, FAACR, Elizabeth Blackburn, PhD, FAACR, Joan Brugge, PhD, FAACR, and Eric Rubin, MD, partnered with the White House Office of Science and Technology Policy to highlight the promise of precision medicine and the need for sustained funding to realize that promise.

Public Workshops

Because of its strong relationships with academic, industry, and government, the AACR is uniquely positioned to bring the cancer community together to overcome obstacles to improved patient care.

- Companion Diagnostics. On March 24, the AACR worked with the U.S. Food and Drug Administration (FDA) and the American Society of Clinical Oncology to host a workshop focused on harmonizing companion diagnostics across a class of targeted therapies. Bringing together patients, researchers, clinicians, drug developers, and diagnostic manufacturers, the workshop emphasized the need for compatibility between diagnostics across a class of drugs. Lance V. Marks, MD, Chairperson of the AACR Diagnostics Policy Subcommittee, served as co-chairperson of the workshop and moderated a panel discussion on comparing diagnostic tests.
- Dose-Finding of Small-Molecule Oncology Drugs. On May 18 and 19, the AACR partnered with the FDA to host a workshop focused on replacing the conventional dose-escalation clinical trial design with an innovative design that bases dose selection on clinical, pharmacologic, and pharmacometric data. Workshop Co-chairpersons included AACR Regulatory Science and Policy Subcommittee members Eriko Rubenstein, MD, and Dani Greene, MD, PhD.
Patients are at the heart of the AACR’s mission to prevent and cure cancer and they are also vital partners in achieving that mission. Through the Survivor and Patient Advocacy Program, the AACR empowers patients, caregivers, and patient advocates to take action on several fronts: funding to sustain scientific inquiry, participation in clinical trials to accelerate discovery, and finding resources for the challenging journey through diagnosis to treatment to survivorship.

In 2015, the magazine appointed William G. Nelson, MD, PhD, as editor-in-chief. Dr. Nelson is the director of the Johns Hopkins Kimmel Cancer Center in Baltimore and a noted medical oncologist and cancer researcher.

Cancer Today was also honored for its design excellence in 2015; the magazine was a finalist in the Feature Design category of Folio magazine’s Ozzie Awards and won a Bronze EXCEL Award for Feature Story Design.

In 2015, patients were at the heart of the AACR’s mission to prevent and cure cancer and they are also vital partners in achieving that mission. Through the Survivor and Patient Advocacy Program, the AACR empowers patients, caregivers, and patient advocates to take action on several fronts: funding to sustain scientific inquiry, participation in clinical trials to accelerate discovery, and finding resources for the challenging journey through diagnosis to treatment to survivorship.

In 2015, the magazine appointed William G. Nelson, MD, PhD, as editor-in-chief. Dr. Nelson is the director of the Johns Hopkins Kimmel Cancer Center in Baltimore and a noted medical oncologist and cancer researcher.

Cancer Today was also honored for its design excellence in 2015; the magazine was a finalist in the Feature Design category of Folio magazine’s Ozzie Awards and won a Bronze EXCEL Award for Feature Story Design.

During the opening ceremony of the Annual Meeting, the AACR honored outstanding men and women who have contributed substantially to the cancer community with Distinguished Public Service Awards. By building relationships in the political arena to ensure funding for cancer research; by engaging the public in understanding cancer research; by creating partnerships to streamline the regulatory process for innovative cancer therapies; and by building relationships in the international community to promote cancer control, these individuals advance the AACR’s mission.
The foundation of the AACR is a diverse and dedicated membership, numbering over 35,000 investigators from around the world. These members are the heart of the cancer research community, working together in the global effort to prevent and cure cancer. Participation in cutting-edge AACR programs provides members with vital opportunities to foster important relationships and collaborations across the entire spectrum—from early-career researchers to senior investigators, from academia to industry, and from scientists to patient advocates. Members of the AACR make critical discoveries in all areas of inquiry, from epidemiological, prevention, and basic science to translational and clinical research.

Active Members:
Established laboratory researchers, physician-scientists, clinicians, and population scientists

Associate Members:
Young laboratory scientists and physicians-in-training (graduate students, medical students and residents, and clinical and postdoctoral fellows)

Student Members:
Undergraduate and high school students

Emeritus Members:
Active members who have reached the age of 70 years

Affiliate Members:
Other health-care professionals (practicing oncologists, nurses, laboratory technicians, non-scientific corporate professionals, and patient advocates)

58 Nobel Laureates have been members of the AACR.
103 Patient advocates are members of the AACR.
2,658 Individuals have been AACR members for more than 25 years.
143 Individuals have been AACR members for more than 50 years.
101 Countries are represented by AACR members.
Cancer touches everyone, affecting patients and their loved ones regardless of their age, ethnicity, or gender. To maximize patient benefit, the AACR works to ensure that the cancer workforce is as diverse as the community of patients it serves. For decades the AACR has pursued this goal by identifying, training, and mentoring talented investigators in populations that are underrepresented in the scientific community. These efforts are coordinated by three vital groups: Minorities in Cancer Research (MICR), Women in Cancer Research (WICR), and the Associate Member Council (AMC).


- The innovative AACR-MICR Distinguished Lectureship Series brings the AACR’s world-class scientific programming to the campuses of Minority Serving Institutions, to inspire young minority students and educators at these institutions to pursue a career in cancer research. The 2015 Lecture series was held on November 16 at Clark Atlanta University, Atlanta, Georgia. Organized by chairpersons John M. Carethers, MD, and Rick A. Kittles, PhD, the lecture program was titled “Diversities in proactive cancer: Outcomes to biomarkers.”
- This past year marked the 10th anniversary of the AACR Minority Scholar in Cancer Research Awards program. These awards support the education and training of minority researchers and increase the visibility and recognition of innovators in cancer research. Through a generous grant from the National Cancer Institute’s Center to Reduce Cancer Health Disparities, the program has supported more than 1,000 trainees since its establishment.

**AACR Women in Cancer Research (2015 Council Chairperson: Victoria M. Richon, PhD)**

- The AACR Women in Cancer Research Scholar Awards enhance the education and training of women scientists while increasing their visibility. In 2015, a total of 30 young investigators attended the AACR Annual Meeting through the awards. The program was also expanded in 2015 to support attendance at Special Conferences, enabling early-career female investigators to focus in on their chosen areas of research.
- The AACR-Women in Cancer Research Charlotte Friend Memorial Lectureship was established in honor of Charlotte Friend, PhD, renowned virologist and discoverer of the Friend virus, to recognize a scientist who has made major contributions to the field of cancer research and furthered the advancement of women in science. In 2015, the eighteenth annual lecture was delivered by Sara A. Courtneidge, PhD, Oregon Health and Science University, Portland, Oregon. Dr. Courtneidge delivered her award lecture, titled “Cancer cell invasion and metastasis,” at the AACR Annual Meeting in Philadelphia.

**AACR Associate Member Council (2015 Chairperson: Mark D. Stewart, PhD)**

- In 2015, the Associate Member Council launched three new AMC-led committees. The Communications Committee enhances communication with Associate Members by providing them with information on the AACR and AMC programming, career advancement, and professional development. The Fundraising Committee increases awareness of and support for the AACR and for cancer research. The Program Committee creates career development content and fosters new and existing networking opportunities for Associate Members.
- The AMC recognizes the importance of advocating for increased funding for early-career cancer scientists. In 2015, a representative member of the AMC attended the “Rally for Medical Research Hill Day,” where the AACR joined with more than 300 organizations from across the country to advocate for robust, sustained, and predictable increases in funding for the National Institutes of Health.
LEADERSHIP

AACR OFFICERS AND DIRECTORS

Officers

JOSÉ BASELGA, MD, FAACR
President
Memorial Sloan Kettering Cancer Center
New York, New York

NANCY E. DAVIDSON, MD
President Elect
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

GEORGE D. DEMETRI, MD
Vice President
Dana-Farber Cancer Institute
Boston, Massachusetts

WILLIAM N. HAIT, MD, PHD, FAACR
Treasurer
Janssen Research and Development, LLC
Raritan, New Jersey

CARLOS L. ARTEAGA, MD, FAACR
Past President
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

JAMES P. ALLISON, PHD, FAACR
Chief Executive Officer
University of Texas MD Anderson Cancer Center
Houston, Texas

MICHAEL A. CALIGIURI, MD
American Association for Cancer Research
Philadelphia, Pennsylvania

Board of Directors

Outgoing AACR President (2014—2015)
Carlos L. Arteaga, MD, FAACR (right), hands the gavel to incoming President José Baselga, MD, PhD, FAACR (left) at the AACR Annual Business Meeting of Members.

The AACR thanks its officers and members of the board of directors for their vision, their wisdom, and their tireless efforts on behalf of the cancer research community.
World-class scientists work with leaders in finance, law, healthcare, and nonprofit management to guide the fundraising and funding activities of the AACR Foundation. Their expert stewardship ensures that 88 cents of every dollar raised by the foundation goes to support lifesaving cancer science.

Mitchell R. Stoller, Executive Director of the AACR Foundation, thanks supporters of the AACR at the Partners in Progress Reception during the AACR Annual Meeting 2015.
The AACR shapes the landscape of cancer research through its scientific task forces, convening experts from multiple disciplines to define, evaluate, and foster emerging areas of inquiry. Task forces focus attention and resources on these promising areas, generating a critical mass of interest and discovery to move the field forward.

When a task force generates a critical mass of interest in an emerging area of research, the AACR promotes further progress in that area. These member groups create communities of interest that build working relationships and foster collaboration.
Applying scientific discoveries to improve the lives of cancer patients requires generous financial support from all sectors of the community — from government agencies and nonprofit organizations; from corporate partners; and from patients, caregivers, family, and friends. The AACR Foundation brings these sectors together, directing their varied interests toward the common goal of preventing and curing cancer.

Thanks to the efforts of the AACR Foundation and the generosity of its supporters, AACR leadership can make decisions based upon scientific need, investing in emerging areas of research by supporting conferences, projects, and investigators that offer long-term promise as well as immediate impact for patients.

“We are proud to support the work of AACR cancer researchers.”

– Mitchell R. Stoller, AACR Foundation Executive Director

Research grants were awarded in 2015.

$60 million
In donations funded AACR member scientists worldwide.

88 cents
Of every dollar donated to the AACR Foundation supports the lifesaving cancer research of members of the AACR.
The inaugural recipients of the AACR June L. Biedler Scholar-in-Training Awards were recognized during the opening ceremony at the AACR Annual Meeting 2015.

Dr. Biedler was a strong supporter of science communications, and her passion is remembered through the AACR June L. Biedler Prize for Cancer Journalism. Announced in 2015, the first prize will be awarded at the AACR Annual Meeting 2016 and will honor outstanding journalistic coverage that enhances the public’s understanding of cancer, its causes, and potential cures.

In 2015, the Foundation launched its first ever marketing campaign to increase public awareness of the AACR's role in funding cancer research. The theme of the campaign was summarized by the tagline “The more we discover why, the more we’ll know how.” The campaign noted that continued progress against cancer depends on better understanding of its complexities, and that the AACR—with the scientific breadth and depth of its members and its ability to foster collaborative relationships—is uniquely positioned to expand that understanding.

The campaign included print, online, radio, television, and billboard advertising in the greater Philadelphia region, in order to maximize awareness of the AACR in its home city. In addition to the new website, the Foundation also reached out globally with an expanded presence on Facebook and Twitter. The campaign was summarized by the tagline “The more we discover why, the more we’ll know how.” The campaign noted that continued progress against cancer depends on better understanding of its complexities, and that the AACR—with the scientific breadth and depth of its members and its ability to foster collaborative relationships—is uniquely positioned to expand that understanding.

Public Education: “The More We Discover Why, The More We’ll Know How”

Since its founding in 2008, the AACR Foundation has been a valuable source of cancer research news and information for cancer patients, advocates, and the public. These educational resources were greatly expanded in 2015 as part of the launch of a redesigned Foundation website. In addition to the latest research news, Foundation website visitors can access NCI-approved information on cancer types, learn about clinical trials and recent FDA approvals, and read the personal stories of patients who have benefitted from advances in cancer research and of the researchers who made these advances possible.

In 2015, the AACR launched two programs honoring the memory of June L. Biedler, PhD, a longtime AACR member, a former member of the Board of Directors, and a recipient of the AACR G.H.A. Clowes Memorial Award for outstanding accomplishments in cancer research. Dr. Biedler passed away in 2012, but her contributions to the AACR have continued. In remembrance of her pioneering work in drug resistance, the AACR used these funds to establish two new awards: the AACR June L. Biedler Scholar-in-Training Awards and the AACR June L. Biedler Prize for Cancer Journalism.

In addition to the new website, the Foundation also reached out globally with an expanded presence on Facebook and Twitter. The campaign included print, online, radio, television, and billboard advertising in the greater Philadelphia region, in order to maximize awareness of the AACR in its home city. In addition to the new website, the Foundation also reached out globally with an expanded presence on Facebook and Twitter.

The AACR Foundation partnered with race directors and the Rock ‘n’ Roll Marathon Series® to give Runners for Cancer Members opportunities to run in races in more than 25 cities in 2015. The AACR Runners for Research program enables individuals, groups, and companies to channel their passion for running toward a common goal of supporting lifesaving cancer research. The AACR Foundation partnered with race directors and the Rock ‘n’ Roll Marathon Series® to give Runners for Cancer Members opportunities to run in races in more than 25 cities in 2015. The AACR Runners for Research program enables individuals, groups, and companies to channel their passion for running toward a common goal of supporting lifesaving cancer research. The AACR Foundation partnered with race directors and the Rock ‘n’ Roll Marathon Series® to give Runners for Cancer Members opportunities to run in races in more than 25 cities in 2015.
Fostering innovation in cancer science is at the core of the AACR’s mission, and research grants support investigators at all career stages to sustain that innovation. The AACR recognizes the following organizations for their vital support of research grants in 2015:

- Aflac, Inc.
- Amgen, Inc.
- Anonymous
- Bayer
- Breast Cancer Research Foundation
- Bristol-Myers Squibb Oncology
- Debbie’s Dream Foundation: Caring Stomach Cancer
- Fight Colorectal Cancer
- Genentech BioOncology
- Kure B Cancer Research
- Kirk A. and Dorothy P. Landon Foundation
- John and Elizabeth Leonard Foundation
- Michael’s Mission
- Neuroendocrine Tumor Research Foundation
- Ocular Melanoma Foundation
- Pancreatic Cancer Action Network
- Stand Up To Cancer
- Triple Negative Breast Cancer Foundation
- Takeda Oncology, Inc.
- The WWF Foundation, Inc. and the Sarcoma Fund of the QuadW Foundation of Communities Foundation of Texas
- Takeda Oncology, Inc.
- Takeda Pharmaceuticals, reservoir fund (for R&D)
- The WWWW Foundation, Inc. and the Sarcoma Fund of the QuadW Foundation of Communities Foundation of Texas
- Michael Lehman, MD (left), Vice President and Head of Innovation at Takeda Pharmaceuticals, congratulates Cindy Lin, PhD (right), recipient of an AACR-Millennium Fellowship in Multiple Myeloma Research. The fellowship encourages and supports a postdoctoral or clinical research fellow to work in an identified multiple myeloma research lab and to establish a successful career path in the field. Through its partnership with the AACR, Takeda Oncology (formerly Millennium Pharmaceuticals) has provided over $800,000 since 2013 to support research on hemopathological malignancies.

- Lynn M. Matrisian, PhD, MBA, FAACR (left), Vice President of Scientific and Medical Affairs for the Pancreatic Cancer Action Network, presents a Pancreatic Cancer Action Network-AACR Career Development Award (supported by an anonymous foundation) to Nada Y. Kalaany, PhD (right). The award encourages and supports junior faculty to conduct pancreatic cancer research and to establish successful career paths in this field. Through its partnership with the AACR, the Pancreatic Cancer Action Network has provided over $27 million since 2003 to support pancreatic cancer research.

- Ron Hollander (left), Executive Director of the Neuroendocrine Tumor Research Foundation (formerly the Caring for Carcinoid Foundation), presents the Caring for Carcinoid Foundation-AACR Grant for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research to Scott André Oakes, MD (right). The grant supports independent junior and senior investigators to develop and carry out innovative, original and creative research in the area of carcinoid tumors (both gastrointestinal and extragastrointestinal) and pancreatic neuroendocrine tumors. Through its partnership with the AACR, the Neuroendocrine Tumor Research Foundation has provided over $2 million since 2011 to support carcinoid tumor and neuroendocrine tumor research.

- Evan M. Altmanison, PhD, MRCP, ABCH (left), Vice President of Scientific and Medical Affairs for the Pancreatic Cancer Action Network, presents a Pancreatic Cancer Action Network-AACR Career Development Award (supported by an anonymous foundation) to Nada Y. Kalaany, PhD (right). The award encourages and supports junior faculty to conduct pancreatic cancer research and to establish successful career paths in this field. Through its partnership with the AACR, the Pancreatic Cancer Action Network has provided over $27 million since 2003 to support pancreatic cancer research.
The Grateful Acknowledges the individual and organizations whose 2015 donations are funding pioneering cancer research. Visit AAFoundation.org to support lifesaving cancer science.
In 2015, the AACR reported another year of positive financial growth. This financial stability enables the AACR to comprehensively meet the challenges of the cancer problem. Operating revenues increased 6 percent to $80 million and total expenditures closely matched revenues. The net impact of revenues and expenses resulted in an operating surplus of $708,000. As outlined in this report, several major projects were launched in 2015, and the AACR was able to outperform the budget through successful programming, revenue growth, and prudent financial management.

Non-operating activities are primarily related to long-term investments. After six straight years of positive performance in the AACR’s investment portfolio, the market corrected in 2015 and the portfolio experienced negative returns in the amount of $2.2 million. These returns were partly offset by the net operating surplus, resulting in an overall net deficit of $1.5 million for the year. At the end of 2015, the AACR had unrestricted net assets of $55 million, which ensures continued investment in the programs that will accelerate progress toward the prevention and cure of cancer.
THE AACR IN 2016: A LOOK AHEAD

SHAPING THE FUTURE OF CANCER RESEARCH

Strategic Planning: Building the Foundation of the Cancer Research Enterprise

During the past year, the AACR Board of Directors laid a forward-looking initiative to develop a Vision 2020 Strategic Plan for the organization. This planning initiative set goals for markedly reducing cancer incidence and mortality, established scientific priorities to support these goals, and defined the AACR programs that will support these priorities in 2016 and beyond.

Vision 2020: A Roadmap for Growth and Impact – Strategic Goals

• To identify and focus our innovation sciences that is of the highest priority and potential for impact in reducing cancer incidence, morbidity, and mortality.

• To become the primary educational resource for cancer scientists, the broader biomedical science community, and the public.

• To publish and disseminate high-quality cancer science worldwide.

• To meet the professional needs of members and increase international outreach and participation.

• To increase awareness of the AACR among the public.

• To serve as the authoritative voice for cancer research and thereby inform and influence science and public policy.

• To develop and implement a comprehensive financial plan that supports the strategic plan and achieves dynamic growth and increased impact.

AACR Provides Thought Leadership to Biden’s New Initiative to Accelerate Cancer Research

In 2015, the government’s efforts to find a cure for cancer were reinvigorated. The National Cancer Institute (NCI) received its largest annual appropriations increase in 12 years (for FY 2016), and Vice President Joe Biden — still mourning the death of his son, Beau, from brain cancer — called for an “absolute national commitment to end cancer as we know it today.”

Within the first few days of 2016, AACR President José Baselga, MD, PhD, FAACR, led a group of 15 distinguished AACR members from 13 of the top cancer centers and medical institutions representing nine states to meet with Biden’s senior staff and discuss the state of cancer research.

These AACR experts, comprised of AACR Board Members and other AACR leaders, offered insights into initiatives that could help advance the vice president’s vision of “making a decade’s worth of advances in five years.” Just days later, during his 2016 State of the Union Address, President Obama formally announced a national effort to be led by Biden to develop new treatments for cancer.

President and Fellows of the AACR were again called upon a few weeks later to provide their thoughts and guidance at a special session at the World Economic Forum in Davos, Switzerland.

Vice President Biden highlighted the importance of data-sharing initiatives during the session and cited AACR Project GENIE (see pg. 60) during his opening remarks.

As this national effort continues to gain momentum, the AACR will work collaboratively with all stakeholders in the broader cancer research and care community to help chart a course with the goal of conquering the more than 200 diseases we call cancer.

Since then, Biden continues to visit cancer centers across the country to learn about the latest innovations and hear first-hand perspectives from cancer researchers and physician scientists — many of whom are AACR leaders and members — about how to propel cancer research forward.
Noncoding RNAs represent a diverse family of regulatory transcripts that affect every stage of gene expression, from transcription and mRNA stability to mRNA translation. Recent evidence has uncovered critical roles for noncoding RNAs in cancer pathogenesis. Artistic interpretation of noncoding RNAs for the AACR Special Conference on Noncoding RNAs and Cancer, December 4-7, 2015, Boston, Massachusetts

THE AACR IN 2016: A LOOK AHEAD

Project GENIE: Sharing Data to Catalyze Precision Oncology

In November 2015, the AACR announced the launch of Project GENIE (Genomics, Evidence, Neoplasia, Information, Exchange). Project GENIE is a multi-phase, international data sharing project that will link cancer genomic data with clinical outcomes from tens of thousands of cancer patients into a registry that will improve clinical decision-making and guide clinical and translational research.

By linking genotypes to clinical outcomes, the data from project GENIE will help clinicians answer a range of clinical questions:

- Validating Biomarkers: Pooled genotype-phenotype relationships can confirm or refUTE that specific mutations can predict patient responses to drugs.
- Repurposing Drugs: A mutation in a specific cancer type could be identified in other cancer types, suggesting that drugs approved for one cancer may be effective against others. Conversely, a drug that is approved for patients with a particular mutation can be evaluated to determine whether it could successfully treat patients with a different mutation.
- Exploring Rare Cancers: The GENIE registry will ultimately provide the “critical mass” of data necessary to support treatment decisions for rare cancers and rare variants in common cancers.

AACR Project GENIE: Founding Members

Phase 1 Participants

- The Center for Personalized Cancer Treatment, Utrecht, Netherlands
- Dana-Farber Cancer Institute, Boston, Massachusetts
- Institut Gustave Roussy, Villejuif, France
- Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
- Memorial Sloan Kettering Cancer Center, New York, New York
- Princess Margaret Cancer Centre, Toronto, Canada
- Vanderbilt Ingram Cancer Center, Nashville, Tennessee

Informatics Partners

- Sage Bionetworks, Seattle, Washington
- Jillianfer, New York, New York

Think Tank: Shaping the Future of Cancer Prevention — A Roadmap for Integrative Cancer Science and Public Health

Throughout its proud history of setting the research agenda for the cancer community, the AACR has been instrumental in making cancer prevention a major focus of that agenda. From the prohibition of smoking in session rooms (1969) to the first major session on prevention (1979) to the presentation of the AACR-ACS Award for Research Excellence in Cancer Epidemiology and Prevention (1985), the AACR Annual Meeting has provided a forum for pioneering cancer prevention science. As the needs of the field have expanded, the AACR has worked to meet those needs — establishing a multidisciplinary journal with a focus on prevention (Cancer Epidemiology, Biomarkers & Prevention, 1992), the AACR Annual Meeting has provided a forum for promoting cancer prevention science. As the needs of the field have expanded, the AACR has worked to meet those needs — establishing a multidisciplinary journal with a focus on prevention (Cancer Epidemiology, Biomarkers & Prevention, 1992), the AACR Annual Meeting has provided a forum for promoting cancer prevention science.

The field of cancer prevention is at an exciting stage, and once more the AACR is taking the lead to define how integrative cancer prevention science can best support public health. An AACR Think Tank was held in February 2016 to discuss and shape the future of the many fields that comprise cancer prevention. Chaired by Ernest E. Hank, MD, MPH (left), and Scott M. Lippman, MD (right), this meeting convened all stakeholders in the cancer prevention arena to define the past, present, and future of cancer prevention and to determine how the AACR can support the evolution of cancer prevention and improved patient care.